

## Corporate Action Information

**Issue Date:** 13 February 2026

**Effective Date:** 16 February 2026

**Contact:** Derivatives Trading Operations, Tel. +49-69-211-1 12 10

Corporate Action	Handling of Equity Options on multi-listed instruments
<b>Company</b>	<b>AstraZeneca</b>
<b>ISIN</b>	<b>GB0009895292</b>
Options Contracts on Stocks	AZA, AZAE, AZS
Futures Contracts on Stocks	
Equity Total Return Future	
Stock Tracking Future	
Futures Contracts on Dividends of Stocks	

Effective February 2, 2026, AstraZeneca completed a direct listing of its ordinary shares on the NYSE. As a result, the shares have become multi-market securities and are now tradable across London, Stockholm, and New York. This development has led to a change in the depository structure, with Clearstream Europe AG (CEU) now using depository DTCC and processing corporate action events aligned with the US market.

The new structure has created different settlement treatments based on the option's settlement location, particularly concerning the upcoming ex-dividend dates.

GBX-denominated Options on AstraZeneca (Product IDs: AZA, AZAE): Physical deliveries originating from exercise/assignment are instructed by Eurex Clearing AG for settlement in GBP at settlement location Euroclear UK & International (EUI, „CREST“) following the ex-date logic for European markets, considering the standard settlement cycle T+2 in Europe. For the up-coming dividend payment announced by AstraZeneca on 10 February 2026, EUI will use the ex-dividend date of Thursday, 19 February 2026, the same date applied to trades concluded on the London Stock Exchange. Any exercises on this date will be processed as ex-dividend.

SEK-denominated Options on AstraZeneca (Product ID: AZS): Physical deliveries originating from exercise/assignment are instructed by Eurex Clearing AG at settlement location CEU for settlement via T2S. Due to its use of the US depository, CEU will use the ex-date logic for US markets, considering the standard settlement cycle T+1. For the upcoming dividend, announced by AstraZeneca on 10 February 2026, CEU will use an ex-dividend date of Friday, 20 February 2026, the same date applied to trades concluded on the New York Stock Exchange. Consequently, any exercises on Thursday, 19 February

2026, will be processed as CUM-dividend, and CEU will generate a market claim to compensate for the dividend. Please note that this deviates from the ex-date of Thursday, 19 February 2026, published by AstraZeneca for trades concluded on Nasdaq Stockholm.

**All participants with remaining open positions in the above products are required to independently verify settlement details and consult appropriate sources before taking action regarding corporate actions, early exercise and physical settlement.**

Participants are additionally reminded that the reference market in the Contract Specifications serves the purpose of determining a marketplace for the price of the share underlying the contract. Physical deliveries of securities shall be made through a Settlement Location (according to Chapter I Part 1 Number 1.4.2 (2) and Chapter II Part 3 Number 3.6.1 of the Clearing Conditions of the Eurex Clearing AG), which may be different from the reference market specified in the Contract Specifications. Any corporate action carried out in respect of securities relating to transactions in Equity Options, shall be processed by the relevant Settlement Location in accordance with the applicable rules of the relevant Settlement Location, see also [Eurex Circular 096/25](#) and [Eurex Clearing Circular 087/25](#). Information on the settlement location for physical deliveries of securities originating from Eurex options can be found on the Eurex Clearing website under "[Settlement Locations](#)".

Please be aware that Eurex Deutschland will refrain from listing new expiry series for AstraZeneca options with immediate effect. Furthermore, any existing series that do not have open interest will not be offered for trading anymore.